EU Progress on 2030 Clinical Trial Targets: What It Means for Lung Cancer
The EU has published its first report on progress towards its 2030 clinical trial targets, and the early figures point in a promising direction. For people affected by lung cancer, the pace of clinical trials across Europe shapes how quickly new treatments become available. Here is what the latest data shows, and how it connects to the EU Biotech Act.
What the EU is aiming for by 2030
The EU has set clear goals to make Europe a faster, more attractive place to run clinical trials. Two of the headline targets are to authorise 500 additional multinational trials over five years, and to speed up how quickly trials begin recruiting patients once they are approved. Multinational trials are important because they open a study across several countries at once, which usually means more places for patients to take part.
What the first report shows
This is the first quarterly report tracking progress, covering January to March 2026. The trend through the quarter is encouraging. Authorisations of new multinational trials rose month on month, from 58 in January to 84 in February to 110 in March, against a long-term average of 78 a month. The quarter opened slightly below the pace needed to hit the five-year goal, but the rising monthly figures suggest momentum is building.
On speed, around 40 percent of trials are now recruiting their first patient within 200 days of applying. This is the measure the EU is using to track how quickly research reaches the people it is designed to help.
Cancer leads clinical trial activity in Europe
Cancer is the most studied area across EU trials. In the report it appears under the heading “neoplasms”, which is the medical term for tumours and covers all types of cancer, including lung cancer. Put simply, cancer research attracts more clinical trial activity in Europe than any other area of medicine.
The report does not break this figure down by cancer type, so it does not tell us exactly how many trials are lung cancer specific. What it does show is that lung cancer belongs to the busiest area of clinical research in Europe, which means faster approvals and quicker recruitment across the system tend to benefit oncology, and lung cancer within it.
What this could mean for people affected by lung cancer
Clinical trials are often the slowest part of bringing a new treatment to people. Lung cancer treatment is moving quickly, with new targeted therapies and immunotherapies emerging all the time, and trials are the route by which those options are tested and eventually approved. When trials start sooner and fill their places faster, promising treatments can reach patients earlier. That is why progress on these targets is worth following.
How this connects to the EU Biotech Act
This work sits alongside the EU Biotech Act, a wider effort to shorten development timelines and make it easier to run trials across borders. Together, the 2030 targets and the Biotech Act point towards a faster and more joined up research environment in Europe.
Read more about what the EU Biotech Act means for people living with lung cancer
Prefer the short version? Read our fact sheet